Skip to main content

Sandra Swain, M.D.

Equibles does not estimate personal net worth.

Get an email with a short summary when Immunome Inc. publishes a filing, an earnings call transcript or a press release.

Get IMNM alerts

About Sandra Swain, M.D.

Sandra Swain, M.D. is recorded as Board Member at Immunome Inc. (IMNM) since April 25, 2024. Immunome Inc. reported in an 8-K filed April 25, 2024 that Sandra Swain, M.D. was appointed Class III director, effective April 25, 2024. Immunome Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunome Inc. includes Clay B. Siegall, Ph.D. (CEO), Clay Siegall (CEO), Corleen Roche (CFO) and 7 others.

“Effective April 25, 2024 (the "Appointment Date"), the Board of Directors (the "Board") of Immunome, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.”
Immunome Inc. Form 8-K, filed April 25, 2024 · Read the filing

Affiliation history

Company network

Current role

Biotechnology · Healthcare

Board Member

2024-04-25–present

Leadership on record at Immunome Inc.

Recent activity